Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…Abstract Number: 1575 • ACR Convergence 2023
Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study
Background/Purpose: Few studies have assessed patient-reported outcome measures in Takayasu arteritis (TAK), a rare large vessel vasculitis. We prospectively analysed fatigue and fibromyalgia in TAK…Abstract Number: 0696 • ACR Convergence 2023
Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study
Background/Purpose: The association of large vessel vasculitis (LVV), whether Takayasu arteritis (TA) or giant cell arteritis (GCA), with inflammatory bowel disease (IBD) is a rare…Abstract Number: 1576 • ACR Convergence 2023
Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria
Background/Purpose: Recently, a joint group of the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) proposed new criteria for…Abstract Number: 0697 • ACR Convergence 2023
Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis
Background/Purpose: The gut microbiome has a critical role in immune homeostasis and there is growing interest in understanding the relationship between the microbiome and autoimmunity.…Abstract Number: 1577 • ACR Convergence 2023
Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome
Background/Purpose: Takayasu's arteritis (TAK) is an autoimmune disease that primarily affects the aorta and its major branches. It has an incidence of 1-3 per million…Abstract Number: 0699 • ACR Convergence 2023
T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by granulomatous inflammation of the aorta and its major branches. The two major forms are giant cell arteritis (GCA)…Abstract Number: 1578 • ACR Convergence 2023
Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis
Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…Abstract Number: 0702 • ACR Convergence 2023
Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Background/Purpose: Cardiac disease has been known to be a major morbidity and mortality cause in vasculitis. Large vessel vasculitis is mostly associated with pericarditis, myocarditis…Abstract Number: 1648 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update
Background/Purpose: Imaging recommendations for primary large vessel vasculitis (LVV) were developed in 2018. Several new studies have emerged since then, and an update of the…Abstract Number: 0706 • ACR Convergence 2023
Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Background/Purpose: Aortitis is the inflammation of the aortic wall, and can be idiopathic or associated with a cluster of infectious and non-infectious diseases (1-3). Periaortitis,…Abstract Number: 1882 • ACR Convergence 2023
Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations
Background/Purpose: Since the development of the EULAR recommendations for the use of imaging in large vessel vasculitis (LVV) in 2017, new data has emerged in…Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »